Australia markets open in 9 hours 31 minutes

NextCure, Inc. (NXTC)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
7.00-0.38 (-5.15%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close7.38
Open7.32
Bid7.10 x 800
Ask7.03 x 900
Day's range7.00 - 7.33
52-week range6.80 - 14.40
Volume449,668
Avg. volume254,828
Market cap193.281M
Beta (5Y monthly)-0.51
PE ratio (TTM)N/A
EPS (TTM)-2.41
Earnings date03 Nov 2021 - 08 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est17.57
  • GlobeNewswire

    NextCure to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

    BELTSVILLE, Md., Sept. 07, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13th. An audio webcast of the pre-recorded presentation will be available on the Investors section of the company’s website at www.

  • GlobeNewswire

    NextCure to Present at the 19th Annual Morgan Stanley Global Healthcare Conference

    BELTSVILLE, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference on September 9th at 12:30 pm Eastern time. A live audio webcast will be available on the Investors section of the company’

  • GlobeNewswire

    NextCure Reports Second Quarter 2021 Financial Results

    BELTSVILLE, Md., Aug. 05, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported second quarter 2021 financial results and provided a business update. “We have made notable progress across all of our clinical programs including several enhancements to the ongoing NC318 Phase 2 monotherapy trial. Clinical sites